Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...
CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...
Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...
The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
TipRanks on MSN
CRISPR Therapeutics AG: Stock surge amid challenges
Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...
Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...
The convergence of genomics, systems biology, and artificial intelligence is transforming the landscape of drug discovery. Modern genomic technologies now ...
Crispr Therapeutics made progress in the third quarter on its commercialization efforts for gene therapy Casgevy and early-stage pipeline candidates, notably CTX310 for high triglycerides and LDL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results